InvestorsHub Logo
Followers 833
Posts 119911
Boards Moderated 17
Alias Born 09/05/2002

Re: DewDiligence post# 3069

Tuesday, 12/27/2022 12:31:42 PM

Tuesday, December 27, 2022 12:31:42 PM

Post# of 7701
From the “risk” section of AEON’s S-4 SEC filing today:

https://www.sec.gov/ix?doc=/Archives/edgar/data/0001837607/000110465922129955/pmgmu-20220930xs4.htm

Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or more of our competitors. For example, Revance has published data related to the treatment of cervical dystonia that indicates that its botulinum toxin may have a duration of effect of at least 24 weeks, which may compare favorably to the duration of effect of ABP-450.

The S-4 filing is pursuant to the proposed SPAC merger between AEON and PMGM (#msg-170682391).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RVNC News